About this episode
Imagine this: 73 million Americans are over 65. Among them, 10-20% experience mild cognitive impairment (MCI), a potential precursor to Alzheimer’s. Yet their primary care doctors, with only 14 minutes per patient, lack the time for crucial neurological screenings. This is a critical gap in our healthcare system, especially as groundbreaking Alzheimer’s research and therapies emerge, making early detection more vital than ever.
That’s where Cx Precision Medicine comes in.
In this episode, we sit down with Sid O’Bryant, PhD, and Danguole Altman, the team behind CxPM, a company in the StartUp Health Alzheimer’s Moonshot Community working to revolutionize early cognitive screening with a simple blood test. Their innovative diagnostic tool is designed to detect neurodegenerative diseases earlier, ensuring patients get the right care at the right time.
O’Bryant’s extensive research, now commercialized by Altman’s leadership, offers a powerful tool for personalized care, enabling earlier, more accurate diagnoses of neurodegenerative diseases. We’ll dive into their unique journeys, the science behind their innovative blood test, and how it’s poised to transform patient care.
Discover how Cx Precision Medicine is empowering patients to get the right care at the right time, streamlining the diagnostic process and ultimately, improving lives. Join us as we explore the future of Alzheimer’s detection and the hope it brings.
Let’s get into it!
Are you ready to tell YOUR story? Members of our Health Moonshot Communities are leading startups with breakthrough technology-driven solutions for the world’s biggest health challenges. Exposure in StartUp Health Media to our global audience of investors and partners – including our podcast, newsletters, magazine, and YouTube channel – is a benefit of ou
